Orthogonal quantification of soluble inducible T-cell costimulator (ICOS) in healthy and diseased human serum
Authors:
Open Access
- 27 June 2021
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 12 (2) , 317-323
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline
This publication has 15 references indexed in Scilit:
- Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapyJournal of Experimental Medicine, 2014
- Effect of Soluble Inducible Costimulator Level and Its Polymorphisms on Age-Related Macular DegenerationDNA and Cell Biology, 2013
- Aberrant production of soluble inducible T-cell co-stimulator (sICOS) and soluble programmed cell death protein 1 (sPD-1) in patients with chronic hepatitis CMolecular Medicine Reports, 2013
- ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T CellsCancer Research, 2012
- Plasmacytoid Dendritic Cells Promote Immunosuppression in Ovarian Cancer via ICOS Costimulation of Foxp3+ T-Regulatory CellsCancer Research, 2012
- Increased production of soluble inducible costimulator in patients with diffuse cutaneous systemic sclerosisArchives of Dermatological Research, 2012
- Ribavirin downmodulates inducible costimulator on CD4+ T cells and their interleukin‐10 secretion to assist in hepatitis C virus clearanceJournal of Gastroenterology and Hepatology, 2011
- Elevated circulating CD4+ICOS+Foxp3+T cells contribute to overproduction of IL-10 and are correlated with disease severity in patients with systemic lupus erythematosusLupus, 2011
- Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosusArthritis & Rheumatism, 2004
- ICOS is essential for effective T-helper-cell responsesNature, 2001